Every 8-K that Briacell Therapeutics Corp. (BCTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BCTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCTX filings page.
BriaCell Therapeutics furnished unaudited interim financial statements and MD&A for its subsidiary BriaPro Therapeutics for the three and nine months ended April 30, 2026. BriaPro reported a net loss of $240,005 for the quarter and $712,236 for the nine-month period, driven mainly by pre-clinical research and development spending of $649,991.
As of April 30, 2026, BriaPro had total assets of $1,321,744, cash of $299,950, current liabilities of $2,239,636 and a working capital deficit of $1,937,495, with an accumulated deficit of $1,892,661. The statements emphasize material uncertainty about BriaPro’s ability to continue as a going concern and its dependence on BriaCell for funding.
During the period, BriaPro acquired BriaCell’s exclusive sCD80 cancer immunotherapy license and related assets by issuing 23,972,589 common shares valued at $846,532, increasing BriaCell’s ownership to about 78%. BriaCell also provided a credit facility of up to $3,000,000, of which $300,000 has been advanced to support sCD80 development.
BriaCell Therapeutics Corp. entered a Placement Agency Agreement with ThinkEquity for a best efforts equity offering of 1,449,300 common shares at $3.25 per share. The offering generated gross proceeds of about $4.71 million before fees and expenses.
The company plans to use the net proceeds for working capital, general corporate purposes, and advancing its business objectives. The shares were issued under an effective shelf registration statement on Form S-3. As compensation, BriaCell paid a cash fee of 7.5% of gross proceeds and issued Placement Agent Warrants to buy 72,465 common shares at an exercise price of $4.0625 per share, exercisable immediately and expiring five years after the agreement date.
BriaCell Therapeutics Corp. is furnishing unaudited interim results for its subsidiary BriaPro Therapeutics and outlining a new oncology licensing deal. For the six months ended January 31, 2026, BriaPro recorded a net loss of $472,231, driven mainly by research and development spending of $433,307. The company has negative working capital of $1,638,799 and a cumulative deficit of $1,652,656, and the statements highlight material uncertainty about its ability to continue as a going concern, with operations funded by BriaCell.
On February 18, 2026, BriaPro agreed to acquire an exclusive worldwide license to develop and commercialize Soluble CD80 (sCD80) for cancer from BriaCell, along with related assets. As consideration and in connection with a $3,000,000 BriaCell credit facility, BriaPro will issue 23,972,589 common shares valued at approximately C$1.18 million, increasing BriaCell’s stake to about 78%. BriaPro will owe a 2% royalty on sCD80 sales to the University of Maryland, Baltimore County. Disinterested shareholders approved the transaction on March 5, 2026, and it closed on March 30, 2026.
BriaCell Therapeutics Corp. held its Annual General and Special Meeting of Shareholders on March 5, 2026. Shareholders owning 3,502,695 common shares were present in person or by proxy, out of 7,250,487 common shares issued and outstanding as of the January 26, 2026 record date.
Shareholders ratified the appointment of MNP LLP as auditors, with 3,431,761 votes for and 70,934 withheld. Six directors were elected, including Dr. Jane Gross, Mr. Jamieson Bondarenko, Dr. William V. Williams, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin Schmieg.
Shareholders also re-approved the Company’s Omnibus Equity Incentive Plan, with 1,524,081 votes for, 362,949 against, and 1,615,665 broker non-votes, maintaining the Company’s existing framework for equity-based compensation.
BriaCell Therapeutics Corp. has entered an asset purchase agreement with its majority‑owned subsidiary BriaPro Therapeutics Corp., transferring BriaCell’s exclusive license to develop and commercialize Soluble CD80 for cancer and related assets to BriaPro. As consideration, BriaPro will issue 23,972,589 BriaPro common shares, raising BriaCell’s ownership in BriaPro to about 78% after the transaction. BriaCell will also make available up to $3.0 million to BriaPro through a credit facility to fund research and development, with each drawdown subject to BriaCell’s approval. The deal is expected to close on or around March 12, 2026, subject to approval by disinterested BriaPro shareholders and receipt of an independent third‑party valuation confirming fair market value.
BriaCell Therapeutics Corp. completed a public offering of 4,327,530 Common Units and 1,039,196 Pre-funded Units at $5.59 per Common Unit and $5.589 per Pre-funded Unit, generating aggregate gross proceeds of approximately $30 million before fees and expenses. Each Common Unit includes one common share and one five-year warrant, while each Pre-funded Unit includes a pre-funded warrant priced at $0.001 per share plus one warrant; each warrant is exercisable at $6.93 per share and trades on Nasdaq under the symbol BCTXL. The company also issued placement agent warrants to purchase up to 161,001 common shares at $8.385 per share and paid the placement agent a 6.25% cash fee on gross proceeds. BriaCell plans to use the net proceeds for working capital, general corporate purposes, and to advance its business objectives, with all securities issued under effective Form S-1 registration statements.
BriaCell Therapeutics Corp. reported that its two-thirds owned subsidiary, BriaPro Therapeutics Corp., has filed unaudited condensed interim consolidated financial statements and a management’s discussion and analysis for the three-month period ended October 31, 2025 with securities regulators in British Columbia and Alberta. These BriaPro financial statements and the related discussion are attached to the report as Exhibits 99.1 and 99.2 and are incorporated by reference for informational purposes only. The company notes that this information is being furnished under Regulation FD and is not considered filed for liability purposes under U.S. securities laws.